Plunkett Research Online: Denali Therapeutics

DENALI THERAPEUTICS (DNLI:NAS) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

Denali Therapeutics Inc is a biotechnology company which is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include LRRK2 Inhibitor Program which develops brain penetrant small molecule LRRK2 inhibitor product candidates for .....



Denali Therapeutics
Ticker: DNLI
Exchange: NAS
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone: 1 650 866-8548
Fax:
Address: 151 Oyster Point Boulevard
2nd Floor
South San Francisco, CA 94080 United States

Types Of Business
Industry Ranks

Industry NAICS code:

Vaccines, Skin Replacement Products and Biologicals Manufacturing
ContactsDescription
Ryan WattsCEO/Co-Founder/Director/President
Steve KrognesCFO/Chief Accounting Officer/Treasurer
See More
Denali Therapeutics Inc is a biotechnology company which is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include LRRK2 Inhibitor Program which develops brain penetrant small molecule LRRK2 inhibitor product candidates for .....See More See More

Auditor: Ernst & Young LLP
Legal Advisor:
$USD, In whole numbers,
except marked * or %
2018201720162015
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and AffiliatesTop Salaries
NameTitleSalary (US$)Bonus (US$)
Other ThoughtsCorporate Culture

Apparent Female Officers or Directors: